$2.27
1.79% yesterday
NYSE, May 20, 10:00 pm CET
ISIN
US00445A1007
Symbol
SLRN
Sector
Industry

ACELYRIN Stock price

$2.27
-0.01 0.44% 1M
-2.16 48.76% 6M
-0.87 27.71% YTD
-2.03 47.21% 1Y
-15.73 87.39% 3Y
-15.73 87.39% 5Y
-15.73 87.39% 10Y
NYSE, Closing price Tue, May 20 2025
+0.04 1.79%
ISIN
US00445A1007
Symbol
SLRN
Sector
Industry

Key metrics

Market capitalization $229.17m
Enterprise Value $-175.45m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.61
P/B ratio (TTM) P/B ratio 0.56
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-281.95m
Free Cash Flow (TTM) Free Cash Flow $-286.77m
Cash position $410.59m
EPS (TTM) EPS $-2.69
Short interest 3.85%
Show more

Is ACELYRIN a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

ACELYRIN Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a ACELYRIN forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a ACELYRIN forecast:

Buy
100%

Financial data from ACELYRIN

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.48 0.48
182% 182%
-
-0.48 -0.48
182% 182%
-
- Selling and Administrative Expenses 59 59
25% 25%
-
- Research and Development Expense 222 222
10% 10%
-
-281 -281
13% 13%
-
- Depreciation and Amortization 0.48 0.48
182% 182%
-
EBIT (Operating Income) EBIT -282 -282
13% 13%
-
Net Profit -269 -269
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about ACELYRIN directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACELYRIN Stock News

Neutral
GlobeNewsWire
7 days ago
LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis I...
Neutral
GlobeNewsWire
14 days ago
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today
Neutral
GlobeNewsWire
19 days ago
Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reiterated its confidence that th...
More ACELYRIN News

Company Profile

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Head office United States
CEO Mina Kim
Employees 83
Founded 2020
Website www.acelyrin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today